Other substances

Ombitasvir

An anti-hepatitis C virus drug.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Ombitasvir is a dipeptide derivative (ChEBI), which acts as an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex. It thus inhibits viral replication (NCIt). It is used in the treatment of chronic HCV infection (ChEBI).

Ombitasvir on DrugBank
Ombitasvir on PubChem
Ombitasvir on Wikipedia


Marketed as

Mixture products: HOLKIRA PAK; TECHNIVIE; VIEKIRA PAK; VIEKIRA XR; VIEKIRAX

 

Structure image - Ombitasvir

CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay

Partialy inhibits (IC50 of 75.5 µM; 65% inhibition at 50 µM) the SARS-CoV-2 3C-like protease in vitro.

 Jan/20/2021

AI-suggested references

Link Publication date
Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interacti
Nov/18/2020
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
Feb/22/2022
Export (.csv)